Tag: cardiorenal outcomes
-
Knowledge Domain and Emerging Trends on Dapagliflozin for Heart Failure: A Bibliometric Analysis (2012–2024)
Introduction Dapagliflozin, a leading SGLT2 inhibitor, has evolved from a glucose-lowering agent to a cornerstone therapy for heart failure (HF). Built on pivotal trials like DAPA-HF and DELIVER, dapagliflozin now targets a broad spectrum of HF patients, including those without diabetes. A recent bibliometric analysis of literature from 2012 to 2024 maps the global research…
-
Knowledge Domain and Emerging Trends on Dapagliflozin for Heart Failure: A Bibliometric View (2012–2024)
Introduction: Dapagliflozin as a Cornerstone in Heart Failure Therapy Heart failure (HF) remains a global healthcare challenge with rising prevalence and substantial economic burden. Dapagliflozin, an SGLT2 inhibitor, emerged as a pivotal therapy beyond glucose control, driven by landmark trials such as DAPA-HF. A bibliometric analysis of research from 2012 to 2024 reveals how scientific…
-
Knowledge Gaps and Emerging Trends in Dapagliflozin for Heart Failure: A 2012–2024 Bibliometric Analysis
Introduction Dapagliflozin, a pioneering SGLT2 inhibitor, has evolved from a diabetes medication to a cornerstone therapy for heart failure (HF). Built on pivotal trials such as DAPA-HF and DELIVER, its role now spans reduced and preserved ejection fraction HF subtypes, with ongoing investigations into cardiorenal protection and fibrosis modulation. This article interprets a comprehensive bibliometric…